The most frequently reported adverse effects are gastrointestinal and typically occur during treatment initiation or dose escalation: Nausea (very common): Usually mild to moderate and diminishing over time Diarrhoea (very common): Potentially contributing to dehydration Vomiting (common): Particularly during early treatment phases Constipation (common): Due to delayed gastric emptying Abdominal pain and dyspepsia (common): May affect eating and drinking patterns Decreased appetite (very common): A therapeutic effect that may inadvertently reduce fluid intake Other notable side effects include: Injection site reactions (erythema, pruritus, swelling) Fatigue and dizziness, which may be exacerbated by dehydration Hypoglycaemia, particularly when used with insulin or sulfonylureas (doses of these medications may need to be reduced when starting tirzepatide) Increased heart rate (modest elevation of 2-4 beats per minute) Gallbladder problems including gallstones and inflammation Potential worsening of diabetic retinopathy in patients with pre-existing disease According to NICE guidance , patients should be counselled about these expected side effects before initiating treatment

By week four, many patients find their new appetite set point feels normal, making calorie restriction sustainable rather than restrictive
Glutathione: Tripeptide Antioxidant Research Guide Glutathione is the most abundant non-protein thiol in mammalian cells and the principal cytosolic antioxidant
Crystal structure of maleylacetoacetate isomerase/glutathione transferase zeta reveals the molecular basis for its remarkable catalytic promiscuity
[DOI] [PMC free article] [PubMed] [Google Scholar] 192.Casanova E.L., Baeza-Velasco C., Buchanan C.B., Casanova M.F
10.7717/peerj.18227 35 ShangguanM.ZhengJ.LiuN.ZhaoJ.WangQ